Citations

Clear

904 citation(s) found for "Gordon, S".

Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia
Fink, Stephanie, Jenkins, Robert B. , Paternoster, Sarah F., Smoley, Stephanie A., Stockero, Kimberly J., Nast, Danielle M., Flynn, Heather C., Tschumper, Renee C. , Geyer, Susan M. , Call, Tim G., Jelinek, Diane F., Dewald, Gordon W., Shanafelt, Tait D. , Witzig, Thomas E. , Zent, Clive S. , Call, Timothy G., Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | September 28, 2006 | Volume: 24 | Issue: 28 | Pages: 4634-4641

10.1200/jco.2006.06.9492 | PMID 17008705 Get It

Purpose Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease. There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH. Patients and Methods Between 1994 and 2002, we enrolled 159 patients with previously untreated CLL (83% Rai stage 0/I) on a prospective trial evaluating clonal evolution by FISH. Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years. Results Chromosomal abnormalities detected by FISH at study entry predicted overall survival. Eighteen patients experienced clonal evolution during follow-up. The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years (n = 71; 1.4%) but 17 occurrences (n = 63; 27%) among patients tested after 5+ years. Clonal evolution occurred among 10% of ZAP-70–negative and 42% of ZAP-70–positive patients at 5+ years (P = .008). Conclusion This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease. Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution. These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL.
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response
Winter, Kathryn, Okawara, Gordon, Donohue, John H., Pisters, Peter W. T., Crane, Christopher H. , Greskovich, J.F., Anné, P.R., Bradley, Jeffrey D. , Willett, Christopher G. , Rich, Tyvin A. , Ajani, Jaffer A. , Bradley, Jeffrey

Mayo Clinic

Journal of Clinical Oncology | August 18, 2006 | Volume: 24 | Issue: 24 | Pages: 3953-3958

10.1200/jco.2006.06.4840 | PMID 16921048 Get It

Purpose Preoperative therapy for localized gastric cancer has considerable appeal. We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points. Patients and Methods Patients with localized gastric adenocarcinoma were eligible. A negative laparoscopic evaluation was required. Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel). Resection was attempted 5 to 6 weeks after chemoradiotherapy was completed. Quality of therapy was assessed with other end points. Results Twenty institutions participated. Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III). The pathCR and R0 resection rates were 26% and 77%, respectively. At 1 year, more patients with pathCR (82%) are living than those with less than pathCR (69%). Grade 4 toxicity occurred in 21% of patients. Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98%, 44%, and 63% of patients, respectively. A D2 dissection was performed in 50% of patients. Of 18 major radiotherapy variations, 17 were due to the lack of inclusion of the L3-4 vertebral interphase as prespecified. Conclusion For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting. The quality of surgery improved (50% with D2 dissection) possibly because surgery was part of this trial. With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
P3–009: Application of reliable change methods for identifying abnormal rates of cognitive decline in dementia
Chelune, Gordon J. , Ivnik, Robert J., Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_12 | Pages: No page available

10.1016/j.jalz.2006.05.1276 Get It

Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia
Jelinek, Diane F., Tschumper, Renee C. , Schwager, Susan M., Nowakowski, Grzegorz S. , Dewald, Gordon W., Shanafelt, Tait D. , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | June 30, 2006 | Volume: 24 | Issue: 19 | Pages: 3218-3219

10.1200/jco.2006.06.1077 | PMID 16809747 Get It

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Kelloff, Gary J. , Lippman, Scott M. , Dannenberg, Andrew J. , Sigman, Caroline C. , Pearce, Homer L., Reid, Brian J. , Szabó, Éva , Jordan, V. Craig , Spitz, Margaret R., Papadimitrakopoulou, Vali A., Lotan, Reuben, Aggarwal, Bharat B. , Bresalier, Robert S. , Kim, Jeri , Lu, Karen H. , Thomas, Melanie E., Rhodes, Helen, Brewer, Molly, Follen, Michele , Shin, Dong M. , Parnes, Howard L. , Siegfried, Jill M. , Evans, Alison A., Blot, William J. , Chow, Wong‐Ho , Blount, Patricia L., Wang, Kenneth K. , Lam, Stephen , Lee, J. Jack, Dubinett, Steven M., Engstrom, Paul F., Meyskens, Frank L. , O’Shaughnessy, Joyce , Hawk, Ernest T. , Levin, Bernard, Nelson, William G. , Hong, Waun Ki , Prevention, for the AACR Task Force on Cancer, Lee, J. Jack , Mills, Gordon B. , Arun, Banu , Maley, Carlo C. , Lee, J. Jack, Prevention, for the AACR Task Force on Cancer, Szabo, Eva , Lee, J Jack

Mayo Clinic

Clinical Cancer Research | June 8, 2006 | Volume: 12 | Issue: 12 | Pages: 3661-3697

10.1158/1078-0432.ccr-06-1104 | PMID 16778094 Get It

AbstractThis article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.
Removal of An Orbital Metallic Foreign Body to Facilitate Magnetic Resonance Imaging: Technical Case Report
Deen, H. Gordon , Miller, David A. , Kostick, David A., Jaeckle, Kurt A.

Mayo Clinic

Neurosurgery | April 24, 2006 | Volume: 58 | Issue: 5 | Pages: E999-E999

10.1227/01.neu.0000210216.15668.19 | PMID 16639311 Get It

Abstract OBJECTIVE AND IMPORTANCE: Magnetic resonance imaging (MRI) is the imaging modality of choice for brain tumors and other lesions of the central nervous system. However, this procedure is contraindicated in patients with orbital metallic foreign bodies. In such cases, the usual clinical strategy is to manage the patient without the benefit of MRI scans and, instead, to rely on less sensitive imaging modalities in particular computed tomographic scanning. CLINICAL PRESENTATION: Two patients, one with a posterior fossa mass and one with suspected central nervous system lymphoma, were seen at our institution. MRI scanning was recommended, but had been precluded in both patients by the presence of metal fragments in the orbit. INTERVENTION: In each case, the orbital foreign body was successfully localized and removed. Postprocedure computed tomographic scanning confirmed complete removal. MRI scanning was then performed without difficulty. The first patient underwent posterior fossa craniotomy and removal of the tumor, which proved to be a medulloblastoma. The second patient was found to have evidence of lymphoma in the cranial base and meninges and was treated with radiotherapy and systemic and intrathecal chemotherapy. MRI scanning provided superior diagnostic information and spared both patients the risks and discomfort of myelography and exposure to ionizing radiation from multiple computerized tomographic scans. CONCLUSION: Two patients with central nervous system tumors underwent removal of a metal fragment in the orbit for the specific purpose of facilitating MRI scans. This is a practical, straightforward concept, which should be considered when MRI scanning is needed for optimal patient management.
Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates
Gordon, Kristine A., Toki, Brian E., Yamane, Andrew K., Hering, Michelle A., Cerveny, Charles G., Petroziello, Joseph M., Ryan, Maureen C. , Smith, Leia M., Simon, Ronald , Sauter, Guido , Oflazoglu, Ezogelin, Doronina, Svetlana O., Meyer, Damon L., Francisco, Joseph A., Senter, Peter D. , Copland, John A. , Wood, Christopher G. , Wahl, Alan F., Law, Che‐Leung , Carter, Paul

Mayo Clinic

Cancer Research | February 17, 2006 | Volume: 66 | Issue: 4 | Pages: 2328-2337

10.1158/0008-5472.can-05-2883 | PMID 16489038 Get It

AbstractMetastatic renal cell carcinoma (RCC) is an aggressive disease refractory to most existing therapeutic modalities. Identifying new markers for disease progression and drug targets for RCC will benefit this unmet medical need. We report a subset of clear cell and papillary cell RCC aberrantly expressing the lymphocyte activation marker CD70, a member of the tumor necrosis factor superfamily. Importantly, CD70 expression was found to be maintained at the metastatic sites of RCC. Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin phenylalanine phenylenediamine (AFP) or monomethyl auristatin phenylalanine (MMAF), two novel derivatives of the anti-tubulin agent auristatin, mediated potent antigen-dependent cytotoxicity in CD70-expressing RCC cells. Cytotoxic activity of these anti-CD70 ADCs was associated with their internalization and subcellular trafficking through the endosomal-lysosomal pathway, disruption of cellular microtubule network, and G2-M phase cell cycle arrest. The efficiency of drug delivery using anti-CD70 as vehicle was illustrated by the much enhanced cytotoxicity of antibody-conjugated MMAF compared with free MMAF. Hence, ADCs targeted to CD70 can selectively recognize RCC, internalize, and reach the appropriate subcellular compartment(s) for drug release and tumor cell killing. In vitro cytotoxicity of these ADCs was confirmed in xenograft models using RCC cell lines. Our findings provide evidence that CD70 is an attractive target for antibody-based therapeutics against metastatic RCC and suggest that anti-CD70 ADCs can provide a new treatment approach for advanced RCC patients who currently have no chemotherapeutic options. (Cancer Res 2006; 66(4): 2328-37)
GCUNC-45 Is a Novel Regulator for the Progesterone Receptor/hsp90 Chaperoning Pathway
Chadli, Ahmed , Abel, M. Greg, Jackson, Twila A., Gordon, David F. , Wood, William M., Felts, Sara J. , Horwitz, Kathryn B. , Toft, David O., Graham, J. Dinny

Mayo Clinic

Molecular and Cellular Biology | February 14, 2006 | Volume: 26 | Issue: 5 | Pages: 1722-1730

10.1128/mcb.26.5.1722-1730.2006 | PMID 16478993 Get It

Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis
Lu, Karen H. , Patterson, Andrea P., Marquez, Rebecca T., Atkinson, E. Neely, Baggerly, Keith, Ramoth, Lance R., Rosen, Daniel , Hellström, Ingegerd, Smith, David, Hartmann, Lynn C. , Fishman, David A. , Schmandt, Rosemarie , Whitaker, Regina S. , Bast, Robert C. , Wang, Lin , Liu, Jinsong , Smith, David, Berchuck, Andrew , Gershenson, David M. , Mills, Gordon B. , Bast, Robert C

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 10 | Pages: 3291-3300

10.1158/1078-0432.ccr-03-0409 | PMID 15161682 Get It

Abstract Purpose: Advanced-stage epithelial ovarian cancer has a poor prognosis with long-term survival in less than 30% of patients. When the disease is detected in stage I, more than 90% of patients can be cured by conventional therapy. Screening for early-stage disease with individual serum tumor markers, such as CA125, is limited by the fact that no single marker is up-regulated and shed in adequate amounts by all ovarian cancers. Consequently, use of multiple markers in combination might detect a larger fraction of early-stage ovarian cancers. Experimental Design: To identify potential candidates for novel markers, we have used Affymetrix human genome arrays (U95 series) to analyze differences in gene expression of 41,441 known genes and expressed sequence tags between five pools of normal ovarian surface epithelial cells (OSE) and 42 epithelial ovarian cancers of different stages, grades, and histotypes. Recursive descent partition analysis (RDPA) was performed with 102 probe sets representing 86 genes that were up-regulated at least 3-fold in epithelial ovarian cancers when compared with normal OSE. In addition, a panel of 11 genes known to encode potential tumor markers [mucin 1, transmembrane (MUC1), mucin 16 (CA125), mesothelin, WAP four-disulfide core domain 2 (HE4), kallikrein 6, kallikrein 10, matrix metalloproteinase 2, prostasin, osteopontin, tetranectin, and inhibin] were similarly analyzed. Results: The 3-fold up-regulated genes were examined and four genes [Notch homologue 3 (NOTCH3), E2F transcription factor 3 (E2F3), GTPase activating protein (RACGAP1), and hematological and neurological expressed 1 (HN1)] distinguished all tumor samples from normal OSE. The 3-fold up-regulated genes were analyzed using RDPA, and the combination of elevated claudin 3 (CLDN3) and elevated vascular endothelial growth factor (VEGF) distinguished the cancers from normal OSE. The 11 known markers were analyzed using RDPA, and a combination of HE4, CA125, and MUC1 expression could distinguish tumor from normal specimens. Expression at the mRNA level in the candidate markers was examined via semiquantitative reverse transcription-PCR and was found to correlate well with the array data. Immunohistochemistry was performed to identify expression of the genes at the protein level in 158 ovarian cancers of different histotypes. A combination of CLDN3, CA125, and MUC1 stained 157 (99.4%) of 158 cancers, and all of the tumors were detected with a combination of CLDN3, CA125, MUC1, and VEGF. Conclusions: Our data are consistent with the possibility that a limited number of markers in combination might identify >99% of epithelial ovarian cancers despite the heterogeneity of the disease.
Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon
Marquez, Rebecca T., Baggerly, Keith, Patterson, Andrea P., Broaddus, Russell, Atkinson, E. Neely, Smith, David I., Hartmann, Lynn C. , Fishman, David A. , Whitaker, Regina S. , Bast, Robert C. , Lu, Karen H. , Liu, Jinsong , Frumovitz, Michael , Smith, David I., Berchuck, Andrew , Gershenson, David M. , Mills, Gordon B. , Bast, Robert C

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 17 | Pages: 6116-6126

10.1158/1078-0432.ccr-04-2509 | PMID 16144910 Get It

Abstract Purpose: Epithelial ovarian cancers are thought to arise from flattened epithelial cells that cover the ovarian surface or that line inclusion cysts. During malignant transformation, different histotypes arise that resemble epithelial cells from normal fallopian tube, endometrium, and intestine. This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble. Experimental Design: Expression of 63,000 probe sets was measured in 50 ovarian cancers, in 5 pools of normal ovarian epithelial brushings, and in mucosal scrapings from 4 normal fallopian tube, 5 endometrium, and 4 colon specimens. Using rank-sum analysis, genes whose expressions best differentiated the ovarian cancer histotypes and normal ovarian epithelium were used to determine whether a correlation based on gene expression existed between ovarian cancer histotypes and the normal tissues they resemble. Results: When compared with normal ovarian epithelial brushings, alterations in serous tumors correlated with those in normal fallopian tube (P = 0.0042) but not in other normal tissues. Similarly, mucinous cancers correlated with those in normal colonic mucosa (P = 0.0003), and both endometrioid and clear cell histotypes correlated with changes in normal endometrium (P = 0.0172 and 0.0002, respectively). Mucinous cancers displayed the greatest number of alterations in gene expression when compared with normal ovarian epithelial cells. Conclusion: Studies at a molecular level show distinct expression profiles of different histologies of ovarian cancer and support the long-held belief that histotypes of ovarian cancers come to resemble normal fallopian tube, endometrial, and colonic epithelium. Several potential molecular markers for mucinous ovarian cancers have been identified.